Resultados de búsqueda - Sandra E. Dunn
- Mostrando 1 - 20 Resultados de 32
- Ir a la Siguiente Página
-
1
-
2
-
3
-
4
MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition por Arezoo Astanehe, Melanie Finkbeiner, Martin Krzywinski, Abbas Fotovati, Jaspreet Dhillon, Isabelle M. Berquin, Gordon B. Mills, Marco A. Marra, Sandra E. Dunn
Publicado 2012Artigo -
5
Identification of ROCK1 kinase as a critical regulator of Beclin1-mediated autophagy during metabolic stress por Aditi U. Gurkar, Kiki Chu, Lakshmi Raj, Richard Bouley, Seung‐Hwan Lee, Young‐Bum Kim, Sandra E. Dunn, Anna Mandinova, Sam W. Lee
Publicado 2013Artigo -
6
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes por Golareh Habibi, Samuel Leung, Jennifer Law, Karen A. Gelmon, Hamid Masoudi, Dmitry Turbin, Michaël Pollak, Torsten O. Nielsen, David G. Huntsman, Sandra E. Dunn
Publicado 2008Artigo -
7
-
8
The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1 por Arezoo Astanehe, Melanie Finkbeiner, Payman Hojabrpour, Karen To, Abbas Fotovati, Ashleen Shadeo, Anna L. Stratford, Wan L. Lam, Isabelle M. Berquin, Vincent Duronio, Sandra E. Dunn
Publicado 2009Artigo -
9
Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells por Anna L. Stratford, Christopher J. Fry, Curtis Desilets, Alastair Davies, Yong‐Yeon Cho, Yvonne Li, Zigang Dong, Isabelle M. Berquin, Philippe P. Roux, Sandra E. Dunn
Publicado 2008Artigo -
10
Targeting YB-1 in HER-2 Overexpressing Breast Cancer Cells Induces Apoptosis via the mTOR/STAT3 Pathway and Suppresses Tumor Growth in Mice por Cathy Lee, Jaspreet Dhillon, Michelle Y.C. Wang, Yuanyuan Gao, Kaiji Hu, Eugene Park, Arezoo Astanehe, Mien‐Chie Hung, Peter Eirew, Connie J. Eaves, Sandra E. Dunn
Publicado 2008Artigo -
11
Nuclear detection of Y-boxprotein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer por Edgar Dahl, Abdelaziz En‐Nia, Frank Wiesmann, Renate Krings, Sonja Djudjaj, Elisabeth Breuer, Thomas J. Fuchs, Peter J. Wild, Arndt Hartmann, Sandra E. Dunn, Peter R. Mertens
Publicado 2009Artigo -
12
YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification por Alastair Davies, Irene Barrett, Mary Rose Pambid, Kaiji Hu, Anna L. Stratford, Spencer A. Freeman, Isabelle M. Berquin, Steven Pelech, P. Hieter, Christopher A. Maxwell, Sandra E. Dunn
Publicado 2011Artigo -
13
YB-1 Expression and Phosphorylation Regulate Tumorigenicity and Invasiveness in Melanoma by Influencing EMT por Corinna Kosnopfel, Tobias Sinnberg, Birgit Sauer, Christian Busch, Heike Niessner, Anja Schmitt, Stephan Forchhammer, Cornelia Grimmel, Peter R. Mertens, Stephan Hailfinger, Sandra E. Dunn, Claus Garbe, Birgit Schittek
Publicado 2018Artigo -
14
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours por Jill E. Kucab, Cathy Lee, Ching‐Shih Chen, Jiuxiang Zhu, C. Blake Gilks, Maggie C.U. Cheang, David G. Huntsman, Erika Yorida, Joanne T. Emerman, Michaël Pollak, Sandra E. Dunn
Publicado 2005Artigo -
15
Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1) por Kristen M. Reipas, Jennifer Law, Nicole Couto, Sumaiya Islam, Yvonne Li, Huifang Li, Artem Cherkasov, Karen Jung, Amarpal S. Cheema, Steven J.M. Jones, John A. Hassell, Sandra E. Dunn
Publicado 2013Artigo -
16
Disulfiram, a drug widely used to control alcoholism, suppresses self-renewal of glioblastoma and overrides resistance to temozolomide por Joanna Triscott, Cathy Lee, Kaiji Hu, Abbas Fotovati, Rachel Berns, Mary Rose Pambid, Margaret Luk, Richard E. Kast, Esther Kong, Eric Toyota, Stephen Yip, Brian Toyota, Sandra E. Dunn
Publicado 2012Artigo -
17
Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2 por Joyce C. Wu, Cathy Lee, Daniel Yokom, Helen Jiang, Maggie C.U. Cheang, Erika Yorida, Dmitry Turbin, Isabelle M. Berquin, Peter R. Mertens, Thomas Iftner, C. Blake Gilks, Sandra E. Dunn
Publicado 2006Artigo -
18
Targeting p90 Ribosomal S6 Kinase Eliminates Tumor-Initiating Cells by Inactivating Y-Box Binding Protein-1 in Triple-Negative Breast Cancers por Anna L. Stratford, Kristen M. Reipas, Kaiji Hu, Abbas Fotovati, Rachel Brough, Jessica Frankum, Mandeep Takhar, Peter H. Watson, Alan Ashworth, Christopher J. Lord, Annette Lasham, Cristin G. Print, Sandra E. Dunn
Publicado 2012Artigo -
19
Preferential Dependence of Breast Cancer Cells versus Normal Cells on Integrin-Linked Kinase for Protein Kinase B/Akt Activation and Cell Survival por Armelle A. Troussard, Paul C. McDonald, Elizabeth D. Wederell, Nasrin M. Mawji, Nolan R. Filipenko, Karen A. Gelmon, Jill E. Kucab, Sandra E. Dunn, Joanne T. Emerman, Marcel B. Bally, Shoukat Dedhar
Publicado 2006Artigo -
20
Polo-Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice por Cathy Lee, Abbas Fotovati, Joanna Triscott, James Chen, Chitra Venugopal, Ash Singhal, Christopher Dunham, J. M. Munro Kerr, Maïté Verreault, Stephen Yip, Hiroaki Wakimoto, Chris Jones, Aarthi Jayanthan, Aru Narendran, Sheila K. Singh, Sandra E. Dunn
Publicado 2012Artigo
Herramientas de búsqueda:
Materias Relacionadas
Biology
Cancer research
Cancer
Gene
Genetics
Cell biology
Medicine
Internal medicine
Biochemistry
Breast cancer
Kinase
Molecular biology
Oncology
Signal transduction
Protein kinase B
Phosphorylation
Cancer stem cell
Cell
Cell cycle
Chemistry
Carcinogenesis
Medulloblastoma
PI3K/AKT/mTOR pathway
Bioinformatics
CD44
Cancer cell
Cell culture
Gene silencing
P70-S6 Kinase 1
Stem cell